N-[3-(benzyloxy)phenethyl]formamide | 475086-53-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-[3-(benzyloxy)phenethyl]formamide
• 英文别名: 1-[3-(benzyloxy)phenyl]-2-(formylamino)ethane；N-[2-(3-phenylmethoxyphenyl)ethyl]formamide
• CAS: 475086-53-4
• 化学式: C₁₆H₁₇NO₂
• 分子量: 255.316
• InChiKey: DMIFZLFDXCNADE-UHFFFAOYSA-N

物化性质

• 沸点：
  476.9±33.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[3-(benzyloxy)phenethyl]formamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 2-[3-(benzyloxy)phenyl]-N-methylethylamine
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES

  摘要：

  公开号：

  EP1400518B1
• 作为产物：
  描述：

  3-苯氧基苯乙胺 、 甲酸乙酯 以 乙醇 为溶剂， 反应 22.0h， 以42%的产率得到N-[3-(benzyloxy)phenethyl]formamide
  参考文献：
  名称：

  Structure–activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists

  摘要：

  To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivatives was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation. Structure-activity relationship studies on the side chain containing the carboxylic acid moiety of the lead compound 5c showed that the length of the linker and the presence of the concatenating nitrogen atom adjacent to the pyrazine ring are critical for the antiaggregatory activity. This study led to the discovery of 2-amino-5,6-diphenylpyrazine derivatives 8c, 15a, and 15b. which showed potent inhibition of platelet aggregation with IC50 values of 0.2 mu M. Among these compounds, 15b is an orally available and long-lasting prostacyclin receptor agonist which is promising for the treatment of various vascular diseases. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.08.010

文献信息

• Heterocyclic compound derivatives and medicines
  申请人：——

  公开号：US20040102436A1

  公开（公告）日：2004-05-27

  The present invention provides a compound which is useful as a PGI 2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: 1 (R 1 and R 2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR 5 , O, S, or ethylene, R 5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH 2 , R 3 and R 4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了一种作为PGI2受体激动剂有用的化合物和制药组合物。本发明涉及一种制药组合物，其包括由以下式子[1]表示的化合物：1（其中R1和R2相同或不同，每个表示可选择取代的芳基，Y表示N或CH，Z表示N或CH，A表示NH、NR5、O、S或乙烯，R5表示烷基，D表示烷基或烯基，E表示苯基或单键，G表示O、S或CH2，R3和R4相同或不同，每个表示氢或烷基，Q表示羧基、烷氧羰基、四唑基、氨基甲酰基或N-(烷基磺酰)氨基甲酰基），或其药学上可接受的盐作为活性成分。
• HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1400518B1

  公开（公告）日：2007-01-17
• US7205302B2
  申请人：——

  公开号：US7205302B2

  公开（公告）日：2007-04-17
• Structure–activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists
  作者：Tetsuo Asaki、Taisuke Hamamoto、Yukiteru Sugiyama、Keiichi Kuwano、Kenji Kuwabara

  DOI：10.1016/j.bmc.2007.08.010

  日期：2007.11

  To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivatives was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation. Structure-activity relationship studies on the side chain containing the carboxylic acid moiety of the lead compound 5c showed that the length of the linker and the presence of the concatenating nitrogen atom adjacent to the pyrazine ring are critical for the antiaggregatory activity. This study led to the discovery of 2-amino-5,6-diphenylpyrazine derivatives 8c, 15a, and 15b. which showed potent inhibition of platelet aggregation with IC50 values of 0.2 mu M. Among these compounds, 15b is an orally available and long-lasting prostacyclin receptor agonist which is promising for the treatment of various vascular diseases. (C) 2007 Elsevier Ltd. All rights reserved.